title: Hepatosplenic alphabeta T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gammadelta hepatosplenic T-cell lymphoma.
abstract: Hepatosplenic gammadelta T-cell lymphoma is a recently identified entity in which lymphoma cells bearing the gammadelta T-cell receptor (TCR) infiltrate the sinusoids of the liver and the sinuses of the splenic red pulp and bone marrow, without lymph node involvement. It is also characterized by a recurrent cytogenetic finding, isochromosome 7q (i7q10). The authors report a case of hepatosplenic lymphoma of alphabeta T-cell phenotype that shares the same clinical, histologic, and cytogenetic characteristics of the previously described hepatosplenic gammadelta T-cell lymphoma. Fluorescent in situ hybridization performed with chromosome 7 probes showed the typical pattern of isochromosome 7q. Genomic analysis of the TCR gamma locus failed to detect a clonal rearrangement. This unique case of hepatosplenic lymphoma of alphabeta T-cell phenotype supports the possibility that lymphoid populations of different alphabeta or gammadelta phenotype that share similar homing and presumably functional properties could give rise to lymphomas displaying similar clinical and pathologic findings.
authors.affiliation: Département de Pathologie, CHU Henri Mondor, Créteil, France.
authors.forename: F
authors.initials: F
authors.lastname: Suarez
authors.forename: I
authors.initials: I
authors.lastname: Wlodarska
authors.forename: F
authors.initials: F
authors.lastname: Rigal-Huguet
authors.forename: M
authors.initials: M
authors.lastname: Mempel
authors.forename: N
authors.initials: N
authors.lastname: Martin-Garcia
authors.forename: J P
authors.initials: JP
authors.lastname: Farcet
authors.forename: G
authors.initials: G
authors.lastname: Delsol
authors.forename: P
authors.initials: P
authors.lastname: Gaulard
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D002897:Chromosomes, Human, Pair 7; D003520:Cyclophosphamide / Q000008:administration & dosage; D004273:DNA, Neoplasm / Q000032:analysis; D004317:Doxorubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D006801:Humans; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D018404:Isochromosomes; D008113:Liver Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000378:metabolism; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000378:metabolism; D013160:Splenic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D013601:T-Lymphocytes / Q000276:immunology*; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D004273:DNA, Neoplasm; D016693:Receptors, Antigen, T-Cell, alpha-beta; D016692:Receptors, Antigen, T-Cell, gamma-delta; D001761:Bleomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; D014751:Vindesine; D011241:Prednisone